Zobrazeno 241 - 250
of 2 311
pro vyhledávání: ''
Autor:
Eugene Zhu, Els Vercammen, Kris Deprince, Irakli Kokhreidze, Ilya Safonov, Rubi Li, Lia Abshilava, Mikheil Janjalia, Bruce Kimelblatt, Iryna Litvin, Kuntegowda C. Lakshmaiah, Igor Bondarenko, Ranjan Kumar Mohapatra, Yaroslav Sparyk, Liang Xiu, Brian Leyland-Jones, Beka Samkharadze, Gia Nemsadze, Oksana Tarasova, Sergey Polenkov, Peter Bowers, Vitaliy Smirnov, Vladimir Vladimirov
Publikováno v:
Journal of Clinical Oncology. 34:1197-1207
Purpose An open-label, noninferiority study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat anemia in patients receiving chemotherapy for metastatic breast cancer. Methods Women with hemoglobin ≤ 11.0 g/dL, receivi
Autor:
Chiun-Sheng Huang, Christian Jackisch, Michael Untch, A Armour, David W. Hillman, Jo Anne Zujewski, Eleanor McFadden, Stella Dolci, Véronique Diéras, Jośe Baselga, Amylou C. Dueck, Sergei Tjulandin, Edith A. Perez, Antonio C. Wolff, Holger Eidtmann, Frances M. Boyle, Young-Hyuck Im, Kathleen I. Pritchard, Ian E. Smith, Thomas M. Suter, Andrew P. Holmes, Evandro de Azambuja, Giuseppe Viale, Serena Di Cosimo, Liu Tong-hua, Eileen Holmes, Binghe Xu, Aron Goldhirsch, Richard D. Gelber, Henry L. Gomez, Ann E. McCullough, Martine Piccart-Gebhart, István Láng, Nadia Harbeck, Phuong Dinh
Publikováno v:
Journal of Clinical Oncology. 34:1034-1042
Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human epidermal growth factor 2–positive breast cancer and increases the pathologic complete response in the neoadjuvant setting, but their role as adjuvant therapy rema
Autor:
Jeffrey E. Gershenwald, Charles R. Scoggins, Kelly M. McMasters, Peter D. Beitsch, B. Scott Davidson, Douglas S. Reintgen, Michael J. Edwards, Arnold J. Stromberg, James S. Goydos, Michael E. Egger, Marshall M. Urist, Stephan Ariyan, Jeffrey J. Sussman, Merrick I. Ross, Lee Hagendoorn, Robert C.G. Martin, R. Dirk Noyes
Publikováno v:
Journal of Clinical Oncology. 34:1079-1086
Purpose The Sunbelt Melanoma Trial is a prospective randomized trial evaluating the role of high-dose interferon alfa-2b therapy (HDI) or completion lymph node dissection (CLND) for patients with melanoma staged by sentinel lymph node (SLN) biopsy. P
Autor:
Sara A. Dudley, Ben Y. Durkee, Martin T. King, Erqi L. Pollom, Jeremy D. Goldhaber-Fiebert, Yushen Qian, Kathleen C. Horst, J. Shaffer, Iris C. Gibbs, Daniel T. Chang
Publikováno v:
Journal of Clinical Oncology. 34:902-909
Purpose The Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) study showed a 15.7-month survival benefit with the addition of pertuzumab to docetaxel and trastuzumab (THP) as first-line treatment for patients with human epidermal growth f
Autor:
Shannon Puhalla, Kimberly L. Blackwell, Eric P. Winer, Alarice C. Lowe, Roisin M. Connolly, Kenneth R. Hess, N. Ryabin, Nathalie Y. R. Agar, Jeffrey S. Wefel, Christina I. Herold, Nan Lin, Sarah Farooq, Polly A. Niravath, Mothaffar F. Rimawi, Elizabeth V. Lawler, Ian E. Krop, Nuhad K. Ibrahim, Rachel A. Freedman, Catherine Van Poznak, Minetta C. Liu, Beverly Moy, Michelle E. Melisko, Antonio C. Wolff, Rebecca Gelman
Publikováno v:
Journal of Clinical Oncology. 34:945-952
Purpose Evidence-based treatments for metastatic, human epidermal growth factor receptor 2 (HER2)–positive breast cancer in the CNS are limited. Neratinib is an irreversible inhibitor of erbB1, HER2, and erbB4, with promising activity in HER2-posit
Autor:
Val Gebski, Paul de Souza, Ian C. Marschner, Sherene Loi, Chee Khoon Lee, Angelo Di Leo, Michael F. Press, Charles E. Geyer, David Cameron, Sarah J. Lord, John Simes, Stephen R. D. Johnston, Lucy Claire Davies, Catherine E. Ellis
Publikováno v:
Journal of Clinical Oncology. 34:936-944
Purpose We examined the prognostic and predictive value of serum human epidermal growth factor 2 (HER2) extracellular domain (sHER2) in patients with advanced breast cancer treated with lapatinib using data from three randomized trials. Patients and
Autor:
Sophie Sun, Ronald L. Burkes, Cheryl Ho, Helen Anderson, Wendy Lam, Barbara Melosky, Vincent T. Ho, Christopher W. Lee, Natasha B. Leighl, Robert Davis Winston, Janessa Laskin, Nevin Murray, Quincy Chu, Desiree Hao
Publikováno v:
Journal of Clinical Oncology. 34:810-815
Purpose Erlotinib is an epidermal growth factor receptor inhibitor approved for patients with advanced non–small-cell lung cancer (NSCLC) whose epidermal growth factor receptor expression status is positive or unknown. Although it is efficacious, e
Autor:
Dimity Hall, Peter S. Hammerman, David M. Jackman, Geoffrey R. Oxnard, Priyanka Shivdasani, Lynette M. Sholl, Pasi A. Jänne, Jennifer C. Heng, Suman Verma, James Christensen, Suzanne E. Dahlberg, Mark M. Awad, Daniel O. Savukoski
Publikováno v:
Journal of Clinical Oncology. 34:721-730
Purpose Non–small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical, pathologic, and genomic characteristics of patients with cancer with MET e
Autor:
Bogdana Balas, Alessandra Bearz, Ramaswamy Govindan, Peter N. Morcos, James Chih-Hsin Yang, Luigi De Petris, Annabelle Monnet, Brett G.M. Hughes, Jin Seok Ahn, Tarek Mekhail, Denis Moro-Sibilot, Ali Zeaiter, Alexander I. Spira, Hervé Lena, Santiago Viteri Ramirez, Sai-Hong Ignatius Ou, Dong Wan Kim, Walter Bordogna
Publikováno v:
Journal of Clinical Oncology. 34:661-668
Purpose Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC), but progression invariably occurs. We investigated the efficacy and safety o
Autor:
Stuart M. Lichtman, Daniel Morganstern, Maria Theodoulou, Harvey J. Cohen, Julie Gralow, Gustav Magrinat, Constance Cirrincione, Arti Hurria, Antonio C. Wolff, Hyman B. Muss, Aminah Jatoi
Publikováno v:
Journal of Clinical Oncology. 34:699-705
Purpose CALGB 49907 showed the superiority of standard therapy, which included either cyclophosphamide/doxorubicin (AC) or cyclophosphamide/methotrexate/fluorouracil over single-agent capecitabine in the treatment of patients age ≥ 65 with early-st